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The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF)
patients who are ineligible for transplant has increased steadily in the last decade. In
parallel, improvements in VAD design have reduced device size, cost, and device-related
complications. These complications include infection and thrombosis which share
underpinning contribution from the inflammatory response and remain common risks
from VAD implantation. An added and underappreciated difficulty in designing a VAD that
supports heart function and aids the repair of damagedmyocardium is that different types
of HF are accompanied by different inflammatory profiles that can affect the response
to the implanted device. Circulating inflammatory markers and changes in leukocyte
phenotypes receive much attention as biomarkers for mortality and disease progression.
However, they are seldom used to monitor progress during and outcomes from VAD
therapy or during the design phase for new devices. Even the partial reversal of heart
damage associated with heart failure is a desirable outcome from VAD use. Therefore,
improved understanding of the interplay between VADs and the recipient’s inflammatory
response would potentially increase their uptake, improve patient lives, and fuel research
related to other blood-contacting medical devices. Here we provide a review of what is
currently known about inflammation in heart failure and how this inflammatory profile is
altered in heart failure patients receiving VAD therapy.
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INTRODUCTION
Heart failure (HF) is a progressive syndrome which occurs when cardiac structure or function
becomes abnormal leading to failure of the heart to deliver oxygen proportionate with
the requirements of metabolizing tissues (1). Symptoms of HF are fairly non-discriminating
(breathlessness, fatigue, and ankle swelling) which makes early diagnosis challenging, particularly
in the elderly and obese (2). HF affects at least 26 million people worldwide (3) with an expected
increase in prevalence of 25% by 2030 (4). The associated healthcare costs, already estimated at $30
billion per year in the USA, are calculated to double in that period (5).
There are three categories of HF based on the measurement of left ventricular ejection fraction
(LVEF). The most well-known and easiest to diagnose is heart failure with reduced ejection fraction
(HFrEF, <40%). Heart failure with preserved ejection fraction (HFpEF, ≥50%) has different
pathophysiological mechanisms (6) and is characterized by stiffening of the left ventricle and
delayed early relaxation which contributes to elevated pressures in the left atrium (7). A newer
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category, heart failure withmid-range ejection fraction (HFmrEF,
40–49%), was established to encourage research into patients
with different symptoms to the other two categories (8).
The progression of HF has been classified into stages A-D
by the American College of Cardiology (ACC) and into stages
I-IV by the New York Heart Association (NYHA) (9, 10). The
stages are interchangeable and are intended to reliably identify
patients for the correct treatment. The Interagency Registry
for Mechanically Assisted Circulatory Support (INTERMACS)
profiling system comes in during stage C/NYHA IIIb (Figure 1)
to determine whether the patient is suitable for transplant
or mechanical circulatory support (MCS) which includes left
ventricular assist devices (VADs) (11).
Heart transplantation remains the ultimate cure for HF with
approximately 7000 hearts transplanted globally per year (12), yet
a vast majority of patients are classed as ineligible for transplant
(13) there is a great need for implantable mechanical circulatory
support such as VADs. Despite VADs being life-saving therapy,
adverse effects such as gastrointestinal bleeding, infection, stroke,
and device thrombosis are still significant complications (14).
As the inflammatory response can contribute to these and other
complications, the aim here is to review the effect of VAD
treatment on the inflammatory profile of HF patients, especially
as it relates to leukocytes.
INFLAMMATION IN HEART FAILURE
Heart failure is the result of stress to the heart due to a number of
causative factors including coronary artery disease, hypertension,
arrhythmias, diabetes, obesity, and age (8). The inflammatory
profile of heart failure has been shown to differ depending on the
ejection fraction category.
A common cause of HFrEF is myocardial infarction (2). MI-
associated injury activates the innate immune system initiating
a cascade of cytokines, chemokines, cell-adhesion molecules,
and cell surface receptors designed to signal reparative cells
to the area of injury (15). Activation of the immune system
and release of inflammatory cytokines in the early stages helps
maintain ventricular function (10) and is necessary to initiate
repair of myocytes (15). During repair, the ventricle is remodeled
which modifies size, shape, and contractility of the cardiac
tissue cells (16, 17). The reduced blood flow at this time is
compensated for by increasing blood volume through limiting
salt release via urine. This places strain on the kidneys and the
Abbreviations:ACC, American College of Cardiology; CF, Continuous Flow; CRP,
C-Reactive Protein; EMP, Endothelial-derived Microparticle; HF, Heart Failure;
HFmrEF, Heart Failure with mid-range Ejection Fraction; HFpEF, Heart Failure
with preserved Ejection Fraction; HFrEF, Heart Failure with reduced Ejection
Fraction; HLA-DR, Human Leukocyte Antigen-D Related; HMII, HeartMate
2; HVAD, HeartWare Ventricular Assist Device; IL, Interleukin; INTERMACS,
Interagency Registry for Mechanically Assisted Circulatory Support; LMP,
Leukocyte-derived Microparticle; LVEF, Left Ventricular Ejection Fraction; MCP-
1, Monocyte Chemotactic Protein 1; MCS, Mechanical Circulatory Support; MIP-
1α, Macrophage Inflammatory Protein 1 alpha; MP, Microparticle; NT-proBNP,
N-Terminal pro Brain Natriuretic Peptide; NYHA, New York Heart Association;
PF, Pulsatile Flow; PMP, Platelet-derived Microparticle; POD, Post-Operative Day;
PVAD, Pulsatile Ventricular Assist Device; TNFα, Tumor Necrosis Factor alpha;
Treg, egulatory T cells; VAD, Ventricular Assist Device.
excess fluids can also affect the liver. Renal dysfunction causes
derangements to metabolic and other circulating factors, which
activates systemic inflammation (18). Excessive inflammation
detrimentally affects repair of the heart and can culminate
in cell damage and death leading to functional impairment
of the myocardium through fibrosis and hypertrophy (15, 19,
20).
HFpEF on the other hand has a slightly different inflammatory
profile. HFpEF can be caused by hypertension and has a
bidirectional relationship with renal dysfunction (18, 21). These
patients have increased blood levels of inflammatory cytokines
such as tumor necrosis factor alpha (TNFα) interleukin-1 beta
(IL-1β), and interleukin-6 (IL-6) (22) postulated to be linked to
dysregulation of the cytokine network by regulatory T (Treg) cells
(21, 23). IL-6 in particular is linked to myocardial fibrosis and
increased myocardial stiffness (21).
The progression of HF can be measured through the
heightened expression of inflammatory cytokines e.g., TNFα,
IL-1, IL-6, IL-18, cardiotrophin-1, Fas ligand (FasL), monocyte
chemoattractant protein 1 (MCP-1), IL-8, and macrophage
inflammatory protein 1 alpha (MIP-1α) (21). These cytokines
can be used as prognostic biomarkers (24–26) as circulating
levels are directly proportional to deterioration in functional
class and cardiac performance (27, 28). Increased levels of
TNFα, IL-1β, IL-6, and galectin-3 (a galactose-specific lectin)
levels can predict adverse outcomes (25). For example, galectin-
3 is associated with inflammation and fibrosis, is a known
mediator of heart failure development and progression (29) and
is elevated significantly in NYHA I-IIIa vs. controls and further
elevated in severe HF NYHA IIIB-IV (30). Another biomarker
of HF includes N-Terminal-pro-BNP (NT-pro-BNP). Natriuretic
peptides regulate volume and blood pressure homeostasis, but
also have roles in the regulation of the immune response with
receptors expressed on T cells, macrophages, and dendritic cells
(31). Blood tests for these are available to diagnose congestive
HF (32).
INFLAMMATION IN RESPONSE TO
VENTRICULAR ASSIST DEVICES
VAD implantation can alleviate symptoms whilst maintaining
a reasonable quality of life for patients with end-stage heart
failure either awaiting or ineligible for heart transplant (10).
VADs can partially reverse some of the pathological processes
involved in advanced HF and restore myocardial function (33).
Inflammatory biomarkers are of diagnostic value to clinicians
to classify HF and monitor progression, but this has not been
translated routinely for use during VAD therapy to predict
positive or negative outcomes.
Given the heightened inflammatory milieu of any potential
VAD recipient, as discussed above, it is critical to better
understand both the impact of the VAD on the patient’s
inflammatory profile and to address this during the development
of new VADs. These same markers could also be used to monitor
patients during VAD therapy for improvement or detecting and
preventing adverse effects.
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FIGURE 1 | Heart failure disease progression. Heart failure disease progression and INTERMACS profile for determination of patient treatment with mechanical
circulatory support (MCS).
Mechanisms Through Which VADs
Influence Inflammation
The mechanisms through which VADs influence inflammation
are yet to be fully understood. First generation VADs, such as
the pneumatic VAD (PVAD; Thoratec, CA, USA), are pulsatile
volume displacement pumps that mimic a physiological pulse
but their size, durability, and complication rates has led to
discontinuation of use. The second and third generation VADs
are continuous flow pumps that have either an axial or centrifugal
rotor. These pumps have the benefit of being smaller in size
to ease implantation, but the continuous flow introduces high
levels of non-physiological shear (34). All VAD types introduce
two crucial elements that affect the immune system: high
levels of shear stress and foreign materials with varying surface
finishes.
Leukocytes are exposed repeatedly to the VAD at 1-min
intervals (average blood flow at rest = 5 L/min) (35). Brief
exposure to high shear sensitizes platelets to activation under
subsequent low insult shear, so it is reasonable to presume
leukocytes might be affected the same way (36). It has been
suggested that shear stress activates leukocytes through structural
changes rather than ligand-induced signal transduction (37).
Interestingly, repeated mechanical deformation at 25 dynes/cm2
of primed neutrophils can return them to a resting state (38), but
above this leads to structural disruption (39).
Leukocytes also contend with different biomaterials and
varying surface finishes throughout the VAD. The surface
properties of these biomaterials drive the foreign body response.
This response begins with protein adsorption (i.e., albumin,
fibrinogen, globulins) at the biomaterial surface creating a highly
dynamic matrix which can make the surface inert, or encourage
cellular activation and adhesion (40). Surface roughness is an
important factor to consider as long-term continuous-flow VADs
(CF-VADs) have highly polished, smooth surfaces near the
rotating impeller (41) to reduce adhesion of proteins and cells
(41). Some VADs, both continuous and axial flow, have sintered
titanium microsphere surfaces to encourage cellular and protein
adherence to form a stable, densely adherent biological lining
(42). This biological lining is hypothesized to “hide” the foreign
material and reduce the immune response.
The complex interactions between leukocytes and VADs,
combined with the pre-existing inflammatory profile of the
VAD recipient, can lead to a plethora of possible inflammatory
outcomes (Figure 2). This could make their use as biomarkers
difficult, but there are some inflammatorymediators that indicate
the effectiveness of VAD therapy. The following section has been
summarized in Table 1.
Clinical Studies of the Inflammatory
Effects of VADs
Clinical studies that measure changes in circulating mediators
have provided insight into how effective VAD therapy is.
Biomarkers most often used include C-reactive protein (CRP),
a common biomarker of systemic inflammation (43), N-
terminal brain natriuretic peptide (NT-proBNP) used to establish
prognosis in heart failure (44), suppressor of tumorigenicity 2
(ST2), a member of the IL-1 receptor family, that signposts
cardiac remodeling and tissue fibrosis (45), and galectin-3, which
is associated with higher risk of mortality (46). Inflammatory
cytokines, mainly IL-6, TNFα, and IL-8, have also been studied
in patients implanted with VADs and provide insight into cardiac
function (21, 25).
Inflammatory and Cardiac Biomarkers
There is an initial elevation of inflammatory markers in response
to VADs but this is largely due to the surgical procedure itself.
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FIGURE 2 | The association between VAD implantation and inflammation. Heart failure has its own distinct inflammatory profile. Ventricular assist device (VAD)
implantation can have both positive and negative outcomes which impact the efficacy of using this treatment. These markers can be used to monitor the progression
of VAD therapy and predict adverse events for early intervention purposes. CRP, C-reactive protein; IL, Interleukin; MCP-1, Monocyte Chemoattractant Protein 1;
MIP-1α, Macrophage Inflammatory Protein 1 alpha; NT-proBNP, N-Terminal pro Brain Natriuretic Peptide; TNFα, Tumor Necrosis Factor alpha.
Increased CRP levels are consistent with inflammation and a
further increase is normal in response to the trauma of surgery
(47). End-stage HF patients already have around 8-fold higher
levels of circulating CRP than the typical healthy reference
value of 0–5 mg/L in serum (48). VAD therapy improves
the inflammatory profile of the patient with levels of CRP
halved compared to pre-operative values within 60 days after
implantation (33). A similar profile is seen in pediatric patients;
pre-VAD CRP levels are abnormally high due to HF (∼35 mg/L),
are exacerbated by surgery, and begin to decrease 1 month post-
implantation with levels returning to the healthy range after 5
months (49).
Circulating NT-proBNP levels decrease significantly in VAD
patients between 24 h pre-implantation and >60 days post-
implantation but still remain abnormally high (33). This
decrease is indicative of normalizing blood volume and
pressure which lessens the strain on the kidneys. However,
the severity of kidney damage and its bidirectional relationship
with HFpEF could be the reason NT-proBNP levels remain
abnormal.
ST2 isconsidered to be a superior cardiac stress biomarker as
levels are not affected by age, BMI, history of HF, anemia, or
renal failure (45). Levels of ST2 decrease in patients implanted
with continuous-flow VADs, but remain abnormally high >60
days post-implantation (33). This suggests cardiac improvement
but not to a point where the patient is no longer at high risk
of mortality. In contrast, those implanted with axial-flow VADs
showed that elevated pre-operative ST2 levels were normalized 1
month post-VAD (50) suggestive of cardiac de-stress and repair.
This would indicate that the axial-flow design is more favorable
toward reverse remodeling.
Galectin-3 levels show a similar trend with higher levels pre-
operatively in HF patients compared to healthy controls (51)
and a decrease during VAD placement (33). However, galectin-
3 levels become elevated again and can even exceed pre-operative
levels after 6 months VAD therapy (30, 51). The reasons for this
are unknown but it might be that the VAD is not supporting
myocardial recovery and that galectin-3 levels identify patients
at higher risk of death.
Cytokines
Circulating cytokines, especially TNFα, IL-6, and IL-8 that
regulate systemic inflammation, are also of interest in HF and
VADs. Elevation of these is linked to poor outcomes (52). TNFα
is elevated in severe HF and can predict mortality (53). Decreases
of TNFα within the myocardial tissue post-VAD implantation
indicate a tissure repair response to VAD treatment although
levels remain higher than in controls(54–56).
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TABLE 1 | The effect of VAD implantation on inflammatory parameters.
Study Effect of VAD implantation
INFLAMMATORY AND CARDIAC BIOMARKERS
Ahmad et al. (29)
Yu et al. (36)
↓CRP halved compared to pre-operative values within 60 days
↓CRP levels in pediatric VAD patients within 1 month
Ahmad et al. (29) ↓NT-proBNP >60 days post-implantation but still abnormally high
Ahmad et al. (29)
Caselli et al. (37)
↓ST2 decreased in CF-VAD patients but still abnormally high
↓ST2 normalized within 1 month in CF-VAD patients
Ahmad et al. (29)
Coromilas et al. (38)
Lok et al. (38)
↓Galectin-3 decreases with VAD placement
↑Galectin-3 becomes elevated, exceeding pre-operative levels after 6 months of VAD therapy
CYTOKINES
Bedi et al. (41) ↓TNFα decreased slightly in myocardium post-VAD but still elevated compared to controls
Corry et al. (44)
Bedi et al. (41)
Caruso et al. (39)
Loebe et al. (47)
↓IL-6 initially elevated but declines below pre-operative levels after 6 weeks
↓IL-6 decreased in the myocardium following VAD support
↑IL-6 increase during VAD support indicative of multiple organ failure
↑IL-6 blood levels higher in CF-VADs than PF-VADs
Corry et al. (44)
Grosman-Rimon et al. (30)
↓IL-8 initially elevated but declines below pre-operative levels after 6 weeks
↑IL-8 blood levels increase to greater than pre-operative levels in CF-VAD by 9 months
LEUKOCYTES
Woolley et al. (49) ↓Decline in peripheral blood leukocyte count with VAD implantation after 60 days
↑Increase in MAC-1 expression on granulocytes with HMII until POD 120
Kirsch et al. (57) ↓Reduced expression of HLA-DR on monocytes in VAD recipients
Ankersmit et al. (52, 53)
Kimballet al. (54, 55)
↓Decrease in CD4T cells and higher levels of CD4 and CD8T cell apoptosis
↓Defective T cell response to inflammatory stimuli
MICROPARTICLES
Diehl et al. (61)
Sansone et al. (62) &
Diehl et al. (61)
↑Increased levels of LMPs in VAD patients
↑Increased levels of LMPs in both HMII and HVAD
Papers describing inflammatory effects by VADs characterized into inflammatory and cardiac biomarkers, cytokines, leukocytes, and microparticles.
IL-6 is increased immediately after VAD implantation with a
decline to below pre-operative levels after 6 weeks (57). However,
patients with higher pre-operative IL-6 (such as those with
HFpEF) are more susceptible to poor early outcomes (52). An
increase in IL-6 post-implantation is associated with multi-organ
failure (58), the main cause of death during early phase MCS
(59). Blood IL-6 concentrations also differ by VAD type being
higher with CF-VAD than with pulsatile (PF-VAD) flow devices
(60). This is likely related to the exposure of leukocytes to non-
physiological flow and high shear levels in CF-VADs leading to
increased activation. As for TNFα, there isan overall reduction in
IL-6 in the myocardium following VAD support (54).
IL-8 showssimilar patterns of change with an immediate
increase post-implantation and a decrease to pre-operative levels
by 4–6 weeks post-operatively (52, 57). There are also differences
by VAD type; while pulsatile and continuous VADs both show a
post-operative decline in IL-8 (61), levels had increased to greater
than pre-operative levels by 9 months post-implantation with
continuous flow devices (43). Again, this could be a feature of
the shear stress effects on leukocyte activation.
Leukocytes
Changes in circulating leukocyte numbers and phenotype
can also provide more detail about the inflammatory changes
associated with VAD implantation. Pre-operatively, VAD
patients have leukocyte counts at the higher end of normal
range, consistent with their inflammatory profile. Overall, VAD
implantation seems to be associated with a decline in peripheral
blood leukocyte counts (62, 63). In patients implanted with either
a PVAD, HeartMate II (HMII; Thoratec), or HVAD (HeartWare,
MA, USA), these leukocyte counts initially increased significantly
(post-operative day (POD) 14) then decreased significantly to
below pre-op levels by POD 60 in all VAD types (62). This would
suggest an improvement in the inflammatory profile.
Despite normalization of leukocyte counts, cell phenotype
is changed ina VAD-dependent manner. Expression of the
activation marker, macrophage antigen-1 (MAC-1), on
granulocytes is a marker for systemic inflammation (64).
MAC-1 was increased significantly in HMII patients at POD 14
and did not return to pre-operative levels until POD 120. For
HVAD patients, an initial small increase in MAC-1 expression at
POD 14 was seen with a return to pre-operative levels by POD
60. This has been linked to the higher rates of and susceptibility
to infection in HMII patients compared to HVAD patients (62)
likely due to design differences: HMII being an axial-flow pump
and the HVAD being a centrifugal pump. Variable increase
in MAC-1 expression might identify patients vulnerable to
recurrent infection and inform intervention.
Additionally, there are wider immune system alterations
caused by VADs. Patients implanted with pulsatile flow VADs
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have a selective reduction in CD4+ T cells, defective proliferative
responses to stimuli such as staphylococcal enterotoxin B, and
higher levels of apoptosis in CD4+ and CD8+ T cells in
comparison to medically treated NYHA class IV patients (65–
68). Disruption of adaptive immune cells contribute to risk of
recurrent infection and sepsis. The effects of continuous-flow
devices on lymphocytes are suspected to be less severe, although
the data are limited. The one study we could identify showed
increased apoptotic activity in CD4+ T cells up to 4 weeks
post-operatively which normalized to baseline after 7 weeks (69).
Potential deactivation of monocytes through a reduced
expression of HLA-DR has also been observed in VAD recipients
and might be a marker of mortality. Patients in intensive care
who died within the first 30 days of implantation exhibited a
lower percentage of monocytes expressing HLA-DR than those
who survived (70). This might be due to immunoparalysis which
during the immediate support phase could hamper tissue repair
for end-organ recovery (52).
Microparticles
Recent years have seen a burgeoning interest in the use of
microparticles (MPs) as biomarkers of inflammatory diseases
such as psoriasis, preeclampsia, pulmonary hypertension, and
heart failure (71, 72). MPs are cell-derived vesicles between
0.1 and 1µm in size that are formed from the outward
blebbing of the plasma membrane due to cell stress (71).
High levels of artificial mechanical stress produced by the
VAD disrupts cells leading to damage, apoptosis, and stress-
induced MP formation (72). MPs can be derived from platelets
(PMPs), leukocytes (LMPs), and endothelial cells (EMPs)
and have strong inflammatory and pro-thrombotic properties.
Significantly elevated levels in VAD patients could be predictive
of adverse events (73). Increased levels of LMPs have been
demonstrated in VAD patients compared to historical controls
and were elevated independently of leukocyte counts, suggesting
that LMPsmight be amarker of vascular inflammation (74). VAD
type might not affect this parameter as both HMII and HVAD
patients had increased LMPs (74, 75).
Summary
Overall, VADs can improve the inflammatory profile of HF
patients through reducing high leukocyte counts and pro-
inflammatory cytokine levels. VAD design, such as biomaterial
choice and levels of shear stress, greatly affects whether
inflammation and the immune system are affected positively or
negatively.
Positive effects identified here includes improving pre-
operative levels of inflammatory markers and cell phenotypes
[e.g., quicker reduction in granulocyte activation in HVAD
patients than HMII (62)]. Negative effects identified here
includes monocyte deactivation, T cell apoptosis (69, 70), and
higher inflammatory cytokine levels (43, 60). Future studies with
newer devices of very different design to the HMII such as the
HVAD and Heartmate III (HMIII) might reveal an improvement
in how these VADs interact with the inflammatory response and
the immune system.
Preclinical Studies for VAD Development
As discussed above, both heart failure and VAD implantation
can affect the inflammatory profile of the patient. Despite this,
the initial stage of VAD development focuses mainly on the
effects on red blood cells through analysis of haemolysis (76).
The need for total blood damage evaluation is not yet widely
recognized and the effects of new VAD designs on leukocyte
number and function and the inflammatory response is only
slowly being included in preclinical evaluation. Studying the
impact of VADs on the inflammatory response during preclinical
testing would allow better understanding and improvement of
the device.
However, there are no published studies of the inflammatory
markers described above during in vitro VAD testing although,
such approaches are being incorporated into preclinical studies
in animals. In a study that involved implanting nine dogs
with and six dogs without VADs, TNFα levels in blood and
renal tissues did not differ after 6 h (77). Changes in leukocyte
counts and activation profiles have been explored in animal
preclinical studies. Cows implanted with the EVAHeart or
HeartMate II had increased in monocyte tissue factor, monocyte-
platelet and granulocyte-platelet aggregates in the first few
days post-operatively. While levels decreased over the next 30
days they remained higher than pre-operative levels and are
suggestive of increased risk of thrombosis (78). However, when
the HVAD was implanted into sheep, leukocyte count remained
within normal ranges (79). This shows that the impact of
very different VAD designs on inflammation can be detected
in vivo.
There are limitations to what can be measured during in vitro
testing due to the models typically being simple blood only loops
but the effects on leukocytes can be assessed. To this end, our
own in vitro studies showed an increase in leukocyte-derived
microparticles emerging in bovine and ovine blood circulated
through the CentriMagTM (63, 80). This increase is important
as the CentriMag is considered the ‘gold standard’ for blood
handling yet there is clearly a so far unappreciated shear-effect
on leukocytes.
SUMMARY
Heart failure is characterized by an inflammatory response,
initiated by injury during myocardial infarction or the repetitive
stress of hypertension on cardiac cells (15, 21, 22). Acute
inflammation initially helps maintain ventricular function and
support tissue repair but eventually this remodels the ventricle
leading to altered function (16, 17). Chronic inflammation can
lead to myocardium dysfunction due to fibrosis, hypertrophy,
and cell death (15). Consequently, pro-inflammatory mediator
expression can be used to map progression of HF, is proportional
to functional class (21, 24–28), and can predict adverse outcomes
(25). Interestingly, right ventricular failure (RVF) post-left VAD
implantation is an emerging major complication. Post-operative
RVF has been associated with higher pre-operative leukocyte
counts and CRP levels suggesting that systemic inflammation
may be contributory after LVAD implantation (81).
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VADs have the potential to partially reverse the pathological
processes involved in the progression of HF and restore
myocardial function (33). The effectiveness of this can be
monitored as a decline in biomarkers such as NT-proBNP, ST2
and the cytokines IL-6 and IL-8 although there are differences in
the pattern of response for pulsatile- vs. continuous-flow devices
(60, 61, 82). Irrespective of the type of device implanted, the
inflammatory profile of patients pre-VAD can be linked to poor
early outcomes (52).
Recent advances in VADs have led to the development of
smaller pumps with better blood damage profiles compared to
their predecessors. The differential effects of continuous-flow vs.
pulsatile flow devices have been noted and there is a growing
trend toward developing pumps with pulsatile capability, such
as the HeartMate III (HMIII, Thoratec), to better maintain the
natural rhythm of the body and reduce blood damage (83).
VAD research is improving our knowledge of the effects of
novel biomaterials and shear stress on blood. Yet, mostly for
practical and ethical reasons, preclinical studies use healthy
human or large animal blood (bovine/ovine/porcine) instead
of blood from heart failure patients which has an inherently
different inflammatory phenotype.
Evidence that VAD treatment improves these inflammatory
parameters and elucidation of the associated mechanisms could
benefit the design of future heart pumps for improved longevity
and quality of life for patients. These changes in inflammatory
markers alone could also be beneficial to clinicians in monitoring
VAD therapy and early-intervention for adverse events such as
sepsis.
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